Aspira Women’s Health Inc. (NASDAQ:AWH) Sees Significant Increase in Short Interest

Aspira Women’s Health Inc. (NASDAQ:AWH) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 537,600 shares, an increase of 20.4% from the October 15th total of 446,600 shares. Based on an average trading volume of 100,200 shares, the days-to-cover ratio is currently 5.4 days. Approximately 4.9% of the shares of the stock are short sold.

Aspira Women’s Health Stock Performance

Shares of Aspira Women’s Health stock opened at $0.75 on Friday. The business has a 50-day moving average of $0.85 and a 200 day moving average of $1.42. Aspira Women’s Health has a 12 month low of $0.72 and a 12 month high of $5.65.

Hedge Funds Weigh In On Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. lifted its holdings in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent reporting period. Institutional investors own 12.19% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AWH. Alliance Global Partners cut their price objective on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research note on Wednesday, August 14th. StockNews.com assumed coverage on shares of Aspira Women’s Health in a research note on Wednesday. They set a “hold” rating for the company.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.